PMID- 16554879
OWN - NLM
STAT- MEDLINE
DCOM- 20060411
LR  - 20080716
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 126
IP  - 7
DP  - 2006 Mar 23
TI  - [Growth factors as neuroprotective treatment in Parkinson disease?].
PG  - 899-901
AB  - BACKGROUND: One of several probable causation theories of Parkinson disease 
      postulates that brain tissue cannot generate sufficient levels of various growth 
      factors required to sustain the viability of dopamine-producing nerve cells in 
      the presence of as yet unknown toxic factors. The study reported here evaluates 
      the ability of externally applied growth factors to protect the dopamine fibres 
      in the basal ganglia in a toxin-induced animal model of the disease. MATERIALS 
      AND METHODS: All animals (rats) were subjected to selective destruction of the 
      dopamine-producing cells in substantia nigra. The rats were divided into three 
      groups. Two groups received intracerebral treatment with either glia-cell derived 
      neurotrophic factor (GDNF) or a combination of brain-derived neurotrophic factor 
      (BDNF) and GDNF. The third group acted as untreated controls and were given 
      sterile saline. The growth factors were infused directly into the brain by an 
      osmotic pump over a period of 28 days. Brain sections taken from all three groups 
      were evaluated by immunocytochemistry. RESULTS: The two groups of rats that 
      received growth factor infusion displayed a significant improvement in their 
      motor behaviour compared to control animals. Immunocytochemistry studies 
      demonstrated that the group receiving a combination of GDNF and BDNF had an 
      increased number of surviving active fibres in the dopamine system striatum in 
      comparison to the control and GDNF groups. In addition the infusion of growth 
      factors resulted in a proliferation of subventricular cells in the basal ganglia. 
      CONCLUSION: The improved motor function following growth factor treatment in this 
      rat model might be due to a delayed retrograde degeneration of the nigrostriatal 
      nerve fibers. Growth factor infusion also clearly stimulated endogenous stem 
      cells and caused their migration towards the striatum. Our observations indicate 
      that the infusion of growth factors into the brain have a symptomatic and 
      neuroprotective effect in this model.
FAU - Torp, Reidun
AU  - Torp R
AD  - Centre for Molecular Biology and Neuroscience (CMBN), Universitetet i Oslo, 
      Postboks 1105 Blindern, 0317 Oslo. torp@basalmed.uio.no
FAU - Singh, Preet Bano
AU  - Singh PB
FAU - Sorensen, Dag R
AU  - Sorensen DR
FAU - Dietrichs, Espen
AU  - Dietrichs E
FAU - Hirschberg, Henry
AU  - Hirschberg H
LA  - nor
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Vekstfaktorer som nevroprotektiv behandling ved Parkinsons sykdom?
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Receptors, Dopamine)
SB  - IM
MH  - Animals
MH  - Brain/cytology/drug effects
MH  - Brain-Derived Neurotrophic Factor/*administration & dosage
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Glial Cell Line-Derived Neurotrophic Factor/*administration & dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - Neuroprotective Agents/*administration & dosage
MH  - Parkinson Disease/*drug therapy/pathology/physiopathology
MH  - Rats
MH  - Receptors, Dopamine/drug effects
EDAT- 2006/03/24 09:00
MHDA- 2006/04/12 09:00
CRDT- 2006/03/24 09:00
PHST- 2006/03/24 09:00 [pubmed]
PHST- 2006/04/12 09:00 [medline]
PHST- 2006/03/24 09:00 [entrez]
AID - 1359468 [pii]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 2006 Mar 23;126(7):899-901.